Publication: Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients
Authors
Caballero-Marcos, Aránzazu ; Salcedo, Magdalena ; Alonso-Fernández, Roberto ; Rodriguez-Peralvarez, Manuel ; Olmedo, María ; Graus Morales, Javier ; Cuervas-Mons, Valentín ; Cachero, Alba ; Loinaz-Segurola, Carmelo ; Iñarrairaegui, Mercedes ; Castells, Lluis ; Pascual, Sonia ; Vinaixa-Aunés, Carmen ; Gonzalez-Grande, Rocio ; Otero, Alejandra ; Tomé, Santiago ; Tejedor-Tejada, Javier ; Álamo-Martínez, José María ; González-Diéguez, Luisa ; Nogueras-López, Flor ; Blanco-Fernández, Gerardo ; Muñoz-Bartolo, Gema ; Bustamante, Francisco Javier ; Fábrega, Emilio ; Romero-Cristóbal, Mario ; Martin-Mateos, Rosa ; Del Rio-Izquierdo, Julia ; Arias-Milla, Ana ; Calatayud, Laura ; Marcacuzco-Quinto, Alberto A. ; Fernández-Alonso, Victor ; Gómez-Gavara, Concepción ; Colmenero, Jordi ; Muñoz, Patricia ; Pons Miñano, José Antonio ; The Spanish Society of Liver Transplantation (SETH)
item.page.secondaryauthor
item.page.director
Publisher
Wiley
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1111/ajt.16599
item.page.type
info:eu-repo/semantics/article
Description
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons. This document is the Published version of a Published Work that appeared in final form in American Journal of Transplantation. To access the final edited and published work see https://doi.org/10.1111/ajt.16599
Abstract
The protective capacity and duration of humoral immunity after SARS-CoV-
2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid
IgG antibodies liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known
prognostic impact in COVID-19.Paired case–control data were also available in 62
liver transplant patients and 62 controls at month 3 after COVID-19.
Liver transplant recipients showed a lower incidence of anti-nucleocapsid
IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–
aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently with persistence of antibodies beyond 6 months after COVID-19.Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS- CoV- 2 antibodies and more pronounced antibody levels decline.
Citation
Am J Transplant. 2021 21:2876–2884.
item.page.embargo
Collections
Ir a Estadísticas
Sin licencia Creative Commons.